Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
General anaesthetic is produced by compound whose having different chemical structure. Some gases as nitrous oxide, volatile liquid like isoflurane and non-volatile solid such as propofol. They act on the cell membranes and have direct relationship between lipid solubility and potency. General anaesthetic agents inhibit excitatory ligand-gated ion channels and increases sensitivity of inhibitory ion channels like gamma amino butyric acid A receptor. The anaesthesia is attended by four steps like analgesia, delirium, surgical anaesthesia and respiratory arrest. The general anaesthesia is generally initiated with intravenous route but inhalational anaesthesia are also incorporated during the surgical procedures.
The North America general anaesthetic drug market is witnessing rapid growth during forecast period 2021-2027. The well-developed healthcare industries are gaining market attention of North America general anaesthetic drug market. The major dynamic factors like increasing number of surgeries such as cardiac, orthopaedic, general surgeries is propelling the market growth of North America general anaesthetic drug market. Technological advancement in drug delivery devices is also refuelling the market growth of North America general anaesthetic drug market. However, high cost of procedures and branded drugs is hindering the market growth of North America general anaesthetic drug market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the drug addiction treatment market. In addition, complete analysis of changes on drug addiction treatment expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. There is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027.
The North America general anaesthetic drug market is segmented by drug molecules, route of administration, end user and country.
The North America general anaesthetic drug market is comprised of drug molecules like isoflurane, desflurane, sevoflurane, ketamine, thiopental, opioids, propofol and other. In which isoflurane is also contributing in the market growth. Isoflurane is general inhalation anaesthetic drug use for induction and maintenance general anaesthetic medicine. The side effect of isoflurane is slow breathing, low blood pressure, abnormality in hear rate. The isoflurane induce muscle relaxant effect of all muscle relaxants most preferably nondepolarizing muscle relaxants and minimum alveolar concentration is reduced by concomitant administration of N2O.
North America general anaesthetic drug market is comprised of route of administration like intravenous and inhalational. In which inhalational is also contributing in the market growth of North America general anaesthetic drug market. Inhalational agents like nitrous oxide, halothane, desflurane, sevoflurane are mostly used agents in practise nowadays. The inhalational general anaesthetic has adverse effects of nephrotoxicity, hepatotoxicity, cardiac arrhythmias, neurotoxicity, postoperative nausea and vomiting, respiratory depression and irritation, malignant hyperthermia and postanaesthetic agitations.
North America general anaesthetic market is comprised of end users like hospitals, speciality clinics and ambulatory surgical centres. In which speciality clinics is also contributing in the market growth. The speciality clinics have skilled professional for the use of anaesthetic. The anaesthetic drugs are very sensitive to doses as slight difference in dose calculation makes impact on patient directly. The rising surgical rate and requirement of skilled professional for surgeries is also propelling the market growth.
North America general anaesthetic drug is studied for countries like US, Mexico and Canada. In which US is anticipated to dominate the market in 2020. The rising rate of surgical procedures is propelling the market growth of region. The rising adoption of technological advanced instruments in surgery is also refuelling the market growth. Increasing collaborations and new product launch is also elevating the market growth of North America general anaesthetic drug market.
The major key players in general anaesthetic drug market are Baxter International Inc. (Us), Hikma Pharmaceuticals Plc (Uk), Pfizer Inc. (Us), Piramal Enterprises Limited (India), Abbvie (Us), Fresenius Se & Co. Kgaa (Germany), Par Pharmaceutical (Us), Teva Pharmaceuticals (Israel), Viatris/Mylan (Us), Novartis Ag (Us), Abbott Laboratories (Us), Astrazeneca Plc (Us), F. Hoffmann-La Roche (Switzerland), Glaxosmithkline Plc (Uk), Gilead Sciences Inc. (Us), Bayer Ag (Germany), Merck & Co. Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (Us), Akorn (Us) and Apotex (Canada) among other are analysed.
August 2020: Fresenius Kabi announced their first medication comprised of smart label embedded with radio-frequency identification technology. The first RFID smart labelled product, Diprivan (propofol) 200mg per 20mL (10mg per mL) injectables Emulsion, USP, was introduced in the US
July 2020: Acacia Pharma a group of PLC granted U.S. FDA approval for BYFAVO (remimazolam) for injection for induction and maintenance of procedural sedation in adults surgical procedures which lasts up to 30 minutes or less.
May 2020: Hikma Pharmaceutical PLC, a multinational pharmaceutical company, announced its propofol injectable emulsion, USP. 20ml, 50ml, 100ml vial in United States.
January 2020: Novartis AG acquired Aspen’s Japanese operations focused on generics and off-patent medicines.
The study comprised of general anaesthetic drug market. In which study analysed the various segments of the market. The general anaesthetic drug market is bifurcated by drug molecule, route of administration and end users. The study also comprised of dominating segment of the market. In the study it is profound that the drug molecule segment is dominated by propofol. Likewise, route of administration is dominated by intravenous route and end user segment is dominated by hospitals. The study also imparts the geographical section of the market and it concludes that United States is dominating the market in 2020. The study also comprised of impact on COVID-19 on the general anaesthetic drug market and it conclude that there is slight slow growth of general anaesthetic drug market is experienced during the COVID-19 situation as there is several restraining factors like mismatch between demand and supply due to complete shutdown in many countries which hampered the transportation of general anaesthetic drugs. The several surgical procedures are post ponded during the time of COVID-19 pandemic. However, activities are resuming and all the pending surgeries are being held nowadays. The market acquired its original state and witnessing rapid growth during the forecast period 2021-2027. The study also imparts the major key players operating in the regions.
Why to buy this report
